SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is under intense scrutiny as it celebrates its 50th anniversary, facing a dual narrative of potential long-term growth through its push into budget-friendly hardware and immediate volatility driven by reported engineering delays on its foldable iPhone and patent infringement setbacks in China. Investors are closely monitoring how the company balances its massive cash reserves against potential settlement costs, while the community remains divided between those bullish on its core ecosystem stability and others wary of its lagging position in the aggressive AI integration race.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing significant price volatility as investors react to the CMS finalization of a 2027 Medicare Advantage rate hike, which came in stronger than previously feared projections. While some market participants are celebrating this as a major relief rally and a catalyst for a short squeeze, others remain cautious due to ongoing sector-wide regulatory uncertainty and concerns over broader market pressures.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending following the formalization of a long-term AI silicon partnership with Google through 2031, which includes custom TPU development and compute capacity commitments for Anthropic. While the community is actively debating the stock's technical support levels and broader sector volatility, many traders are highlighting the deal as a major structural catalyst that reinforces Broadcom's leadership in the hyperscale AI infrastructure space.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is facing significant downward pressure as investors weigh premium valuation concerns and potential macro sensitivity against its role as a key data provider for AI model training. The community is sharply divided, with bulls pointing to the company's long-term data licensing potential and share buyback program, while bears highlight heavy insider selling, concerns over bot-inflated user metrics, and the platform's broader content moderation controversies.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana and other managed care stocks are surging following a finalized Medicare Advantage payment rate from CMS that exceeded initial market fears and projections. Investors are actively discussing the revenue stability this decision provides for the sector, while others remain focused on navigating volatility and assessing the long-term impacts of policy shifts on insurer margins.

Space and Time is the data blockchain securing onchain finance. Backed by Microsoft’s Venture Fund M12, Space and Time connects real-world data to onchain systems to power tokenized assets, stablecoins, institutional markets, and DeFi.  The SXT token is deployed as an ERC-20 token on Ethereum and functions as the network's native utility token. SXT is used for staking, data processing payments, access control, and incentives for data contributors.

Space and Time

Space and Time (SXT) is gaining significant community traction due to its high-profile technological partnerships, including integrations with Microsoft and Samsung, as well as its focus on verifiable, AI-ready data infrastructure. While some investors are bullish on the project's long-term potential and institutional backing, others are debating the impact of recent token unlocks and questioning its short-term price volatility.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is at the center of intense market activity driven by escalating geopolitical tensions in the Middle East and concerns over energy supply disruptions. The community is actively debating the stock's potential as a long-term play on European natural gas needs while closely monitoring the impact of volatile news cycles and heavy institutional short-selling.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a significant leadership overhaul that replaced CEO Peter Greenleaf with Chairman Kevin Tang, a move that the community widely interprets as a clear signal that the company is being positioned for a potential buyout. Investors are closely monitoring how Tangs new management team will leverage existing assets, such as Lupkynis and the Aritinercept pipeline, to maximize shareholder value.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals is in the spotlight as investors await upcoming Phase 2 pediatric trial data for zelicapavir, which the company expects to provide insights into its RSV treatment strategy. Community sentiment remains focused on the potential of Enanta's RSV portfolio and immunology pipeline to address significant unmet market needs despite recent volatility and broader competitive pressures in the biotech sector.

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Bausch + Lomb Corp

Bausch + Lomb Corp.

Bausch + Lomb is currently a focal point of intense market speculation as activist investor JANA Partners builds a stake in The Cooper Companies, aiming to orchestrate a strategic merger or separation involving their contact lens division and $BLCO. This move has sparked enthusiasm among market participants who view the potential consolidation as a major value-unlocking catalyst, though discussions remain shadowed by concerns over the company's long-term debt structure and its complex relationship with parent firm Bausch Health.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ELTX are you concerned they will dilute the price when they release Phase 2 data? They need to raise a lot of money, or partner to complete Phase 3.

$ELTX If you assume ~95/135 patients are MRD-positive (the highest-risk group in resected pancreatic cancer), historical DFS is usually ~6–10 months. With that population mix, you normally wouldn’t expect a long delay in events unless something is slowing recurrence. 
 
A rough model with equal MRD distribution across trial and placebo arms suggests a baseline DFS of around ~9–10 months. For the trial timeline to slip like this, the treatment arm would likely need to be meaningfully longer — something like ~15–18 months — implying a hazard ratio of ~0.5–0.6. 
 
In pancreatic MRD that would be a VERY strong signal. Many oncology approvals occur around HR ~0.7, so anything near ≤0.6 would be notable and could support a registrational path, buyout/partnering interest, and support an MC trajectory towards 1 Billion.

StockTwits Web

Elicio Therapeutics Inc

Grant Forman

StockTwits for iOS

 are you concerned they will dilute the price when they release Phase 2 data? They need to raise a lot of money, or partner to complete Phase 3.

Cbra

@Cbra It will first depend on the quality of the data. Assuming it is clean and &quot;good&quot;, we should see &quot;some&quot; value uptick on the day. But then it all comes down to who are the new buyers of the stock or partners because they have no money.  
 
Now the company may trade to 500M market cap and raise 150M on that which would hurt. 
 
A partner with non-dilutive funding would be ideal.  
 
It is definitely a risk and knowing this company&#39;s history, there is a valid case to assume they will likely not do a great financing.

J. E.

I was thinking of investing a bit more, but after reading the latest filings, not so sure I want to

 It will first depend on the quality of the data. Assuming it is clean and "good", we should see "some" value uptick on the day. But then it all comes down to who are the new buyers of the stock or partners because they have no money.  
 
Now the company may trade to 500M market cap and raise 150M on that which would hurt. 
 
A partner with non-dilutive funding would be ideal.  
 
It is definitely a risk and knowing this company's history, there is a valid case to assume they will likely not do a great financing.